Comparison of cytokeratin 20 RNA and angiogenin in voided urine samples as diagnostic tools for bladder carcinoma

J Cancer Res Clin Oncol

Chen

et al. 2007

Section: Discussionsupporting

confidence: 92%

“…In our series, no correlations were conWrmed between urinary CK-20 and tumor grade, tumor stage or other clinicopathological factors except age. The same results were reported by Eissa et al (2004). However, Jiang et al (2001) found a positive correlation between urinary CK-20 and nodal status (P < 0.05).…”

Section: Discussionsupporting

confidence: 78%

The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine

J Cancer Res Clin Oncol

Chen

et al. 2007

“…BLAST 9 was used to align the sequences. The genomic sequence of UCA1 was analyzed with a Repbase server 10 specialized for human endogenous retrovirus (HERV) genes and aligned with a consensus genomic sequence of HERV-H (17). Open reading frame (ORF) finder 11 and Artemis software 12 were used to analyze the open reading frame.…”

Section: Methodsmentioning

confidence: 99%

Rapid Identification of UCA1 as a Very Sensitive and Specific Unique Marker for Human Bladder Carcinoma

Zhang

Clinical Cancer Research

et al. 2006

421

359

Purpose: The most common genitourinary malignancy in China is bladder transitional cell carcinoma (TCC). Early diagnosis of new and recurrent bladder cancers, followed by timely treatment, will help decrease mortality. There are currently no satisfactory markers for bladder cancer available in clinics. Better diagnostic methods are highly demanded. Experimental Design: In this research, we have used comprehensive expressed sequence tag analysis, serial analysis of gene expression, and microarray analysis and quickly discovered a candidate marker, urothelial carcinoma associated 1 (UCA1). The UCA1 gene was characterized and its performance as a urine marker was analyzed by reverse transcription-PCR with urine sediments. A total of 212 individuals were included in this study, 94 having bladder cancers, 33 ureter/pelvic cancers, and 85 normal and other urinary tract disease controls. Results: UCA1 was identified as a novel noncoding RNA gene dramatically up-regulated inTCC and it is the most TCC-specific gene yet identified. The full-length cDNA was 1,439 bp, and sequence analysis showed that it belonged to the human endogenous retrovirus H family. Clinical tests showed that UCA1assay was highly specific (91.8%, 78 of 85) and very sensitive (80.9%, 76 of 94) in the diagnosis of bladder cancer and was especially valuable for superficial G2-G3 patients (sensitivity 91.1%, 41 of 45). It showed excellent differential diagnostic performance in various urinary tract diseases without TCC. Conclusions: UCA1 is a very sensitive and specific unique marker for bladder cancer. It could have important implications in postoperative noninvasive follow-up. This research also highlights a shortcut to new cancer diagnostic assays through integration of in silico isolation methods with translational clinical tests based on RNA detection protocols.

Diagnostic Cytopathology

“…Higher levels of Cytokeratin‐20 mRNA are expressed in malignant urothelial tissue compared with normal tissue 11, 12. Urinary CK20 mRNA levels are also raised in transitional cell carcinoma 14–16. There are few reports of immunocytochemistry on urine cytology for detection of urothelial carcinoma 20, 21.…”

Section: Discussionmentioning

confidence: 99%

“…Most cytokeratins are ubiquitous except cytokeratin‐20 (CK20), which is expressed in malignant cells of colon, ovary, and urinary bladder but not in benign urothelium 11–13. Urinary cytokeratin‐20 mRNA levels have the advantage of high sensitivity for all grades of tumor and low rates of positivity in healthy adults 14–16…”

mentioning

confidence: 99%

Cytokeratin‐20 immunocytochemistry in voided urine cytology and its comparison with nuclear matrix protein‐22 and urine cytology in the detection of urothelial carcinoma

Srivastava

Arora

Aggarwal

et al. 2011

This study was done on 59 subjects (42 urinary bladder carcinoma patients and 17 non-neoplastic controls). Urine cytology and bladder chek NMP22 test was done on all cases. CK20 immunostaining was performed on archived papanicolaou stained urine cytology smears in 34 cases (27 bladder carcinoma and 7 negative controls). Results of all three tests (cytology, NMP22, and CK20 immunostaining) were compared with histopathology to evaluate the accuracy of individual test. The combination of cytology and NMP22 was compared with combination of cytology and CK20 immunostaining for detection of bladder carcinoma. NMP22 had sensitivity of 92.9% and specificity of 70.6%, as compared with voided urine cytology (sensitivity of 76.2% and specificity of 76.5%) and CK20 immunostaining (sensitivity of 70.4% and specificity of 71.4%). Combination of cytology and NMP22 gave better results (sensitivity of 88.1% and specificity of 88.2%) than combination of cytology and CK20 immunostaining or any other test in isolation.